Tech Company Financing Transactions
Vittoria Biotherapeutics Funding Round
Agent Capital, Global BioAccess Fund and NYBC Ventures participated in a $10 million funding round for Vittoria Biotherapeutics. This venture round closed on 11/12/2024.
Transaction Overview
Company Name
Announced On
11/12/2024
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funds will primarily support the company's Phase 1 clinical trial of its lead oncology candidate, VIPER-101, an autologous, dual-population T cell therapy, as a potential treatment of T-cell Lymphoma.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3675 Market Street 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Website
Email Address
Not Recorded
Overview
Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies while addressing their inherent challenges by strengthening efficacy, improving safety, and broadening therapeutic applicability for patients with difficult-to-treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nicholas Siciliano
Browse more venture capital transactions:
Prev: 11/12/2024: Salesfire venture capital transaction
Next: 11/12/2024: AdipoPharma venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs